Immunotherapy for Ovarian Cancer and How It Works

Ovarian cancer is one of the most complex gynecologic cancers to treat, particularly in advanced stages. While traditional treatments like surgery and chemotherapy have increased survival rates, recurrence is still common. In recent years, immunotherapy has emerged as a hopeful option in oncology, including for ovarian cancer. Although it is primarily experimental in this context, it holds promise, especially for patients with recurrent or treatment-resistant disease.

What Is Immunotherapy?

Immunotherapy is a type of cancer treatment that prompts the body's immune system to identify and destroy cancer cells more effectively. Unlike chemotherapy, which directly kills cancer cells and can also harm healthy cells, immunotherapy uses the body's natural defences. It aims for targeted precision with fewer side effects. The immune system typically eliminates abnormal cells, but cancer can dodge this detection. Immunotherapy helps restore or enhance the immune system's ability to fight cancer.

Why Consider Immunotherapy for Ovarian Cancer?

Ovarian cancer usually responds well to initial chemotherapy, but recurrence rates are high, and later responses tend to diminish. Immunotherapy is being studied for these cases because:

It can assist patients who do not respond to standard chemotherapy.
It may provide longer-lasting effects by teaching the immune system to recognise and target cancer cells if they recur. It offers opportunities for personalised cancer treatment, tailoring therapies to each patient's immune profile and tumor characteristics.

While it's not yet a standard treatment for ovarian cancer, clinical trials are ongoing, and some types of immunotherapy are showing promising results.

How Immunotherapy Works in Ovarian Cancer

In ovarian cancer, tumors often develop ways to avoid immune detection. Immunotherapy aims to counteract this evasion and help the immune system recognise and attack these malignant cells. Here are the main ways immunotherapy can work in ovarian cancer:

Boosting T-cell activity so that immune cells target tumor cells.
Blocking signals (immune checkpoints) that prevent immune attacks.
Introducing immune cells or molecules specifically designed to target ovarian cancer.
Encouraging the production of immune-related proteins (cytokines) to enhance the immune response.
Training the immune system through cancer vaccines to identify tumor-specific markers.

Types of Immunotherapy for Ovarian Cancer

Immune Checkpoint Inhibitors: Tumors can "hide" from immune cells by activating specific inhibitory pathways called immune checkpoints. These pathways include proteins found on immune or tumor cells. Immune checkpoint inhibitors block these interactions, enabling the immune system to target and attack the cancer. Early trials in ovarian cancer show modest benefits with checkpoint inhibitors alone, but combinations with chemotherapy or other treatments seem more promising.
Cancer Vaccines: Unlike preventive vaccines, therapeutic cancer vaccines are made to enhance the immune system's response against existing cancer. These vaccines expose the immune system to tumor-specific antigens-proteins found on cancer cells-helping the body identify and destroy them. In ovarian cancer, several vaccine candidates target specific antigens commonly found in tumors. Early studies suggest these vaccines may stimulate immune memory and work best when combined with other therapies.
Adoptive Cell Therapy (ACT): ACT involves taking immune cells from the patient, modifying or expanding them in the lab, and reintroducing them to combat cancer. These cells are sometimes engineered to recognise ovarian cancer better. There are different forms of ACT:

Tumour-Infiltrating Lymphocytes (TILs) therapy: It uses immune cells already present inside the tumor. CAR T-cell therapy, where immune cells are engineered to carry receptors specific to cancer cells. TCR therapy, which changes T-cell receptors to better recognise tumour antigens. While highly effective in blood cancers, ACT is still being refined for solid tumors like ovarian cancer.
Monoclonal Antibodies: These lab-made antibodies are designed to target specific proteins on cancer cells. They work by:

Marking cancer cells for immune destruction.
Blocking growth signals.
Delivering toxic substances directly to cancer cells.

Some monoclonal antibodies have already shown benefits in ovarian cancer and may be used alongside other immune treatments for better outcomes.

Cytokine Therapy: Cytokines are signalling proteins, such as interleukins and interferons, that help regulate immune responses. Administering synthetic cytokines can enhance immune cell activity, although side effects such as inflammation and fatigue are common. Due to toxicity concerns, modern research focuses on more targeted cytokine delivery, using nanoparticles or combining them with checkpoint inhibitors for added effects.

Effectiveness of Immunotherapy in Ovarian Cancer

The overall effectiveness of immunotherapy in ovarian cancer has been limited when used alone, but it shows promise in combination therapies. Factors that influence effectiveness include:

Tumor mutational burden (TMB): Cancers with more mutations usually respond better.
Presence of immune cells in the tumor (immune infiltration): Tumors with more immune cells show better responses.
Biomarkers like PD-L1 expression: These can help identify patients likely to benefit.
Genetic mutations such as BRCA1/2:Some mutations may increase sensitivity to immune-based treatments.

Though success rates vary, ongoing clinical trials are providing valuable insights, improving patient selection, and guiding combination strategies.

Who Can Receive Immunotherapy for Ovarian Cancer?

Currently, immunotherapy is primarily available through clinical trials. It may be considered for:

Patients with recurrent or resistant ovarian cancer.
Those with specific genetic mutations or biomarkers.
Individuals who have exhausted standard treatment options.
Participants in personalised medicine programs.
Eligibility depends on health status, cancer stage, and test results, including genomic profiling.

Side Effects of Immunotherapy

Immunotherapy is usually well-tolerated; however, it can cause immune-related side effects when the immune system mistakenly attacks healthy tissues. These may include:

Skin rashes
Diarrhea or colitis
Fatigue
Thyroid dysfunction
Lung inflammation (pneumonitis)

Most side effects are manageable with corticosteroids or treatment interruption, but early recognition is key.

Benefits of Immunotherapy

Longer-lasting effects compared to chemotherapy
Potential for remission in some hard-to-treat cases
Better tolerance and fewer systemic side effects
Opens pathways for personalised cancer therapy

Challenges and Future Directions of Immunotherapy in Ovarian Cancer

Despite the promising potential of immunotherapy in cancer treatment, its use in ovarian cancer faces several challenges. One major issue is the relatively low response rate among patients, mainly when immune checkpoint inhibitors are used alone. This indicates that many ovarian tumors create an environment that does not support strong immune responses, limiting the therapy's effectiveness. Additionally, ovarian cancer is a solid tumor, which creates physical and biological barriers that can block immune cell infiltration and activity. This differs from blood cancers, where immunotherapy has shown more promising results.

The future of immunotherapy in ovarian cancer will likely focus on biomarker-driven clinical trials aimed at personalising treatment and improving response rates. There is growing interest in combination therapies that integrate immunotherapy with chemotherapy, targeted therapies, or radiation to enhance outcomes. At the same time, early detection of immune resistance mechanisms may help doctors adjust treatments before they stop working. Advances in cell therapy technologies, such as engineered T-cells and oncolytic viruses, are also expected to play a crucial role in overcoming the challenges of treating solid tumors like ovarian cancer.

Conclusion

Immunotherapy presents a new and exciting avenue in the fight against ovarian cancer. Although it is not yet a standard treatment, its emerging role-especially in cases of recurrence and resistance-marks a significant advancement in the field of oncology. With ongoing research, personalised approaches, and increasing clinical trials, immunotherapy has the potential to transform ovarian cancer care, offering new hope to patients worldwide.